ANORO ELLIPTA 25 MCG — DIN 02418401
VILANTEROL (VILANTEROL TRIFENATATE) : 25 MCG UMECLIDINIUM (UMECLIDINIUM BROMIDE) : 62.5 MCG · GLAXOSMITHKLINE INC · POWDER · wholesale supply in Canada
Health Canada status: MARKETED
What is ANORO ELLIPTA?
ANORO ELLIPTA 25 MCG contains VILANTEROL (VILANTEROL TRIFENATATE) : 25 MCG UMECLIDINIUM (UMECLIDINIUM BROMIDE) : 62.5 MCG. It is listed in the Health Canada Drug Product Database under DIN 02418401, held by GLAXOSMITHKLINE INC, supplied as POWDER for INHALATION administration. Health Canada currently lists it as marketed, status dated 14-Mar-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ANORO ELLIPTA used for?
ANORO ELLIPTA (umeclidinium/vilanterol) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA) indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ANORO ELLIPTA is not indicated for the relief of acute deterioration of COPD. ANORO ELLIPTA is not indicated for the treatment of asthma. The safety and efficacy of ANORO ELLIPTA in asthma have not been established.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Vilanterol And Umeclidinium Bromide cost around the world?
Vilanterol And Umeclidinium Bromide is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Belgium publishes a public; Hungary publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Belgium | public | 11 | 11 | EUR███.██ |
| Spain | PVP con IVA (public price) | 3 | 3 | EUR███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Slovakia | categorised final price | 1 | 1 | EUR███.██ |
17 pack listings across 17 brand entries and 5 price bases, refreshed 05 Sep 2026. Ranges span every Vilanterol And Umeclidinium Bromide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 25 MCG |
|---|---|
| Dosage form | POWDER |
| Route | INHALATION |
| Pack configuration (monograph) | ANORO ELLIPTA is supplied as a disposable grey and red plastic inhaler containing 2 double-foil strips. Each blister on one of the strips contains a white powder mix of micronized umeclidinium bromide (74.2 mcg, equivalent to 62.5 mcg of umeclidinium) and each blister on the other strip contains a white powder mix of micronized vilanterol trifenatate (40 mcg, equivalent to 25 mcg vilanterol). The inhaler is packaged within a moisture-protective foil laminate tray with a desiccant and a peelable foil lid. ANORO ELLIPTA is supplied with either 30 or 7 blisters on each double-foil strip. |
| Storage | Do not store above 30°C. Store in a dry place away from direct heat or sunlight. If stored in the refrigerator, allow the inhaler to return to room temperature for at least an hour before use. Keep out of sight and reach of children. The inhaler is packaged within a moisture-protective foil laminate tray with a desiccant and a peelable foil lid. ANORO ELLIPTA should be safely discarded when the dose counter reads "0" or 6 weeks after it was removed from the foil tray, whichever comes first. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Vilanterol And Umeclidinium Bromide |
|---|---|
| ATC code | R03AL03 |
| AHFS class | 12:12.08.12 ; 12:08.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02418401 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2418401 |
| Brand name | ANORO ELLIPTA |
| Generic / active ingredient | VILANTEROL (VILANTEROL TRIFENATATE) : 25 MCG UMECLIDINIUM (UMECLIDINIUM BROMIDE) : 62.5 MCG |
| Market authorization holder | GLAXOSMITHKLINE INC |
| Health Canada schedule | Prescription |
| ATC code | R03AL03 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R03AL |
| Current status | MARKETED |
| Status date | 14-Mar-2014 |
| Original market date | 2014-03-14 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The recommended and maximum dose is one inhalation of ANORO ELLIPTA 62.5/25 mcg once daily. ANORO ELLIPTA is for oral inhalation only. ANORO ELLIPTA should be administered once-daily at the same time of the day each day. If a dose is missed, the patient should be instructed to take the next dose when it is due. The patient should not be instructed to take an extra dose. Patients should be made aware that for optimum benefit, ANORO ELLIPTA must be used regularly, even when asymptomatic. When beginning treatment with ANORO ELLIPTA, patients who have been taking oral or inhaled, short-acting beta2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
ANORO ELLIPTA is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. ANORO ELLIPTA is contraindicated in patients with severe hypersensitivity to milk proteins. All LABAs are contraindicated in patients with asthma without use of a long-term asthma control medication.
Warnings and precautions
Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of salmeterol (SEREVENT Inhalation Aerosol) or placebo added to patients' usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including vilanterol, one of the active ingredients in ANORO ELLIPTA. ANORO ELLIPTA is only indicated for COPD. The safety and efficacy of ANORO ELLIPTA in patients with asthma have not been established. ANORO ELLIPTA is therefore not indicated for the treatment of asthma. As with other inhaled drugs containing beta2-adrenergic agents, ANORO ELLIPTA should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing a long-acting beta-adrenergic agonist or a long-acting muscarinic antagonist, as an overdose may result. When beginning treatment with ANORO ELLIPTA, patients who have been taking oral or inhaled, short-acting beta2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms. Patients should be made aware that for optimum benefit, ANORO ELLIPTA must be used regularly, even when asymptomatic. ANORO ELLIPTA is not indicated for the treatment of acute episodes of bronchospasm, i.e., as rescue therapy. ANORO ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD. The initiation of ANORO ELLIPTA in this setting is not appropriate. An inhaled, short-acting beta2-agonist should be used to relieve acute symptoms such as shortness of breath. When prescribing ANORO ELLIPTA, the physician must also provide the patient with an inhaled, short-acting beta2-agonist for treatment of acute symptoms. Patients should be advised to have their short-acting beta2-agonist available at all times. As with other inhaled bronchodilators, ANORO ELLIPTA should not be used more often or at higher doses than recommended. ANORO ELLIPTA should not be administered concomitantly with other medicines containing a long-acting beta2-adrenergic agonist or a short- or long-acting muscarinic antagonist (e.g., ipratropium, tiotropium, glycopyrronium, aclidinium), as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. There have been no studies investigating the effect of ANORO ELLIPTA on the ability to perform tasks that require judgement, motor or cognitive skills. The occurrence of headache or blurred vision may influence the ability to drive or to use machinery. Consistent with its antimuscarinic activity, ANORO ELLIPTA should be used with caution in patients with narrow-angle glaucoma or urinary retention. ANORO ELLIPTA, like other antimuscarinic-containing products, should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately should any of these signs or symptoms develop. ANORO ELLIPTA, like other antimuscarinic-containing products, should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any of these signs or symptoms develop. ANORO ELLIPTA is a combination of a long-acting beta2-agonist (vilanterol) an
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC R03AL
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Salbutamol And Ipratropium Bromide | APO-SALVENT-IPRAVENT STERULES · COMBIVENT RESPIMAT · COMBIVENT UDV · IPRAMOL · +3 more | 7 | 3 | Yes |
| Vilanterol, Umeclidinium Bromide And Fluticasone Furoate | TRELEGY ELLIPTA | 2 | 2 | Yes |
| Formoterol, Glycopyrronium Bromide And Budesonide | BREZTRI AEROSPHERE | 1 | 1 | Yes |
| Indacaterol And Glycopyrronium Bromide | ULTIBRO BREEZHALER | 1 | 1 | Yes |
| Formoterol And Aclidinium Bromide | DUAKLIR GENUAIR | 1 | 1 | Yes |
| Indacaterol, Glycopyrronium Bromide And Mometasone | ENERZAIR BREEZHALER | 1 | 1 | Yes |
| Olodaterol And Tiotropium Bromide | INSPIOLTO RESPIMAT | 1 | 1 | Yes |
| Vilanterol And Umeclidinium Bromide | ANORO ELLIPTA | 1 | 1 | Yes |
| Fenoterol And Ipratropium Bromide | DUOVENT UDV | 1 | 0 | Not in Canada |
| Formoterol, Glycopyrronium Bromide And Beclometasone | TRIMBOW | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R03AK | Formoterol And Budesonide · Formoterol And Mometasone · Indacaterol And Mometasone · Salbutamol And Sodium Cromoglicate · Salmeterol And Fluticasone · +1 more | 26 | 20 |
| R03AC | Fenoterol · Formoterol · Indacaterol · Olodaterol · Pirbuterol · +4 more | 81 | 15 |
| R03AA | Epinephrine | 4 | 0 |
| R03AB | Isoprenaline · Orciprenaline | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ANORO ELLIPTA called?
Also recorded in Canada as: Vilanterol trifenatate (GLOBAL), Vilanterol Trifenatate (US), Vilanterol Trifenatate (UK), Umeclidinium bromide / Vilanterol trifenatate (GLOBAL).
The same molecule, Vilanterol And Umeclidinium Bromide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Trelegy Ellipta | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.